Search / Trial NCT00001311

Modified Intraocular Lens to Reduce Eye Inflammation After Cataract Surgery in Uveitis Patients

Launched by NATIONAL EYE INSTITUTE (NEI) · Dec 9, 2002

Trial Information

Current as of December 27, 2024

Completed

Keywords

Cell/Flare Meter Heparin Coating Inflammation Laser Cell Flare Photometry Multicentric Polymethylmetacrylate Specular Micrography Specular Microscopy

ClinConnect Summary

The purpose of this project is to evaluate the ability of a heparin-surface modified intraocular lens to reduce the incidence and severity of post-operative inflammation in patients with uveitis undergoing extracapsular cataract surgery. Patients who have a history of uveitis and have been in remission on steroids and/or cyclosporine or cytotoxic agents for at least three months will be considered for this study. They will be randomized in a masked fashion to either a surface-modified lens or to a non-modified lens of similar design. The intraocular inflammation will be assessed using stand...

Gender

ALL

Eligibility criteria

  • Follow-up Only.

About National Eye Institute (Nei)

The National Eye Institute (NEI), part of the U.S. National Institutes of Health (NIH), is dedicated to conducting and supporting innovative research to understand, prevent, and treat eye diseases and vision disorders. As a leading sponsor of clinical trials, NEI aims to advance knowledge in ocular health through rigorous scientific inquiry and collaboration with researchers, healthcare professionals, and institutions. By fostering the development of new therapies and technologies, NEI plays a pivotal role in enhancing the quality of life for individuals affected by visual impairments and eye conditions.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials